BACKGROUND
Severe Pediatric Allergic Asthma (SPAA) induces a huge economic burden
in terms of direct, indirect and intangible costs. The use of omalizumab
for the treatment of these patients has produced a significant
improvement in several clinical outcomes, but at the same time, the cost
for the management of the disease has also increased.
The aim of this report was to evaluate whether the use of omalizumab is
cost-effective.